NANOG and cancer: The results complete a set of experiments providing evidence that exogenous IL‐6 treatment upregulates MBD2_v2 in TP53 wild‐type LNCaP and RC77T cells (Fig. 3) and that upregulated MBD2_v2 by stable overexpression in RC77T cancer cells upregulates NANOG, SOX2, and SOX9 (Fig. 4G–I).